1. Home
  2. COGT vs AIOT Comparison

COGT vs AIOT Comparison

Compare COGT & AIOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • AIOT
  • Stock Information
  • Founded
  • COGT 2014
  • AIOT 1993
  • Country
  • COGT United States
  • AIOT United States
  • Employees
  • COGT N/A
  • AIOT N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • AIOT Telecommunications Equipment
  • Sector
  • COGT Health Care
  • AIOT Telecommunications
  • Exchange
  • COGT Nasdaq
  • AIOT Nasdaq
  • Market Cap
  • COGT 806.1M
  • AIOT 787.1M
  • IPO Year
  • COGT 2018
  • AIOT N/A
  • Fundamental
  • Price
  • COGT $7.41
  • AIOT $4.36
  • Analyst Decision
  • COGT Buy
  • AIOT Strong Buy
  • Analyst Count
  • COGT 6
  • AIOT 4
  • Target Price
  • COGT $15.20
  • AIOT $10.50
  • AVG Volume (30 Days)
  • COGT 2.4M
  • AIOT 2.3M
  • Earning Date
  • COGT 08-05-2025
  • AIOT 06-16-2025
  • Dividend Yield
  • COGT N/A
  • AIOT N/A
  • EPS Growth
  • COGT N/A
  • AIOT N/A
  • EPS
  • COGT N/A
  • AIOT N/A
  • Revenue
  • COGT N/A
  • AIOT $362,515,000.00
  • Revenue This Year
  • COGT N/A
  • AIOT $21.96
  • Revenue Next Year
  • COGT N/A
  • AIOT $10.74
  • P/E Ratio
  • COGT N/A
  • AIOT N/A
  • Revenue Growth
  • COGT N/A
  • AIOT 169.28
  • 52 Week Low
  • COGT $3.72
  • AIOT $3.70
  • 52 Week High
  • COGT $12.61
  • AIOT $8.71
  • Technical
  • Relative Strength Index (RSI)
  • COGT 64.24
  • AIOT 41.01
  • Support Level
  • COGT $7.07
  • AIOT $4.22
  • Resistance Level
  • COGT $7.50
  • AIOT $4.59
  • Average True Range (ATR)
  • COGT 0.43
  • AIOT 0.23
  • MACD
  • COGT -0.06
  • AIOT -0.01
  • Stochastic Oscillator
  • COGT 55.94
  • AIOT 16.47

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About AIOT PowerFleet Inc. Common Stock

PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.

Share on Social Networks: